Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Psychedelic mushrooms, containing the active ingredient psilocybin, have shown remarkable potential in treating various ...

The government is preparing to fund the use of MDMA and psylocibin, otherwise known as ecstasy and magic mushrooms, as a ...

Compass Pathways has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before ...

Psychedelics have been recreational substances for decades. Now, they're entering the mainstream of psychiatric treatment.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label ...

A Placer County man is sharing his personal story of recovery from severe suicidal depression. David Bartley found relief in ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...